Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data

doi:10.3748/wjg.v25.i15.1840

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6791)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

385

WORD

195

HTML

3876

Figures (1-4)

305

Tables (1-3)

259

Sum=5020

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

716

Download

1055

Sum=1771

Apr 21, 2019 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (22)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Apr 21, 2019; 25(15): 1840-1853
Published online Apr 21, 2019. doi: 10.3748/wjg.v25.i15.1840

Full Size Figure Download Figure

Figure 3 Differential expression of Beclin-1, LC3, and 4E-BP1 tested by immunohistochemical staining in colorectal cancer samples compared to normal tissues. LC3 (P < 0.001) showed higher expression in cancer than in normal tissue, while Beclin-1 (P = 0.248) and 4E-binding protein 1 (P = 0.793) did not. LC3: Microtubule-associated protein 1A/B-light chain 3; 4E-BP1: 4E-binding protein 1.

Citation: Guo GF, Wang YX, Zhang YJ, Chen XX, Lu JB, Wang HH, Jiang C, Qiu HQ, Xia LP. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data. World J Gastroenterol 2019; 25(15): 1840-1853
URL: https://www.wjgnet.com/1007-9327/full/v25/i15/1840.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i15.1840